loading
Schlusskurs vom Vortag:
$71.48
Offen:
$71.88
24-Stunden-Volumen:
1.23M
Relative Volume:
0.81
Marktkapitalisierung:
$7.49B
Einnahmen:
$628.56M
Nettoeinkommen (Verlust:
$141.82M
KGV:
57.75
EPS:
1.26
Netto-Cashflow:
$142.60M
1W Leistung:
+1.48%
1M Leistung:
-13.17%
6M Leistung:
+52.81%
1J Leistung:
+190.38%
1-Tages-Spanne:
Value
$71.17
$74.22
1-Wochen-Bereich:
Value
$69.26
$74.56
52-Wochen-Spanne:
Value
$23.02
$117.33

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
Firmenname
Corcept Therapeutics Inc
Name
Telefon
650.688.8803
Name
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
Mitarbeiter
352
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-17
Name
Neueste SEC-Einreichungen
Name
CORT's Discussions on Twitter

Vergleichen Sie CORT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CORT
Corcept Therapeutics Inc
72.77 7.49B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-11-06 Hochstufung Truist Hold → Buy
2023-04-11 Eingeleitet SVB Securities Market Perform
2023-04-04 Eingeleitet Piper Sandler Overweight
2023-02-15 Herabstufung Jefferies Buy → Hold
2022-08-01 Herabstufung Truist Buy → Hold
2022-07-27 Hochstufung Jefferies Hold → Buy
2022-06-27 Fortgesetzt Canaccord Genuity Buy
2022-02-02 Eingeleitet Canaccord Genuity Buy
2022-01-28 Eingeleitet Truist Buy
2020-08-05 Herabstufung Jefferies Buy → Hold
2019-09-24 Eingeleitet Jefferies Buy
2019-09-06 Eingeleitet H.C. Wainwright Buy
2019-02-04 Herabstufung B. Riley FBR Buy → Neutral
2018-08-10 Bestätigt Stifel Hold
2018-05-31 Herabstufung Stifel Buy → Hold
2018-03-09 Eingeleitet B. Riley FBR, Inc. Buy
2017-08-31 Eingeleitet Stifel Buy
2017-02-02 Eingeleitet Ladenburg Thalmann Buy
2015-04-21 Eingeleitet FBR Capital Outperform
2014-01-13 Herabstufung Stifel Buy → Hold
2013-08-09 Herabstufung Janney Buy → Neutral
2013-08-09 Herabstufung Ladenburg Thalmann Buy → Neutral
2012-02-21 Bestätigt JMP Securities Mkt Outperform
2010-01-06 Hochstufung Ladenburg Thalmann Neutral → Buy
2008-07-17 Eingeleitet Rodman & Renshaw Mkt Outperform
2007-06-21 Hochstufung Punk, Ziegel & Co Mkt Perform → Accumulate
Alle ansehen

Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten

pulisher
Apr 30, 2025

Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years? - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

BlackRock, Inc. Reduces Stake in Corcept Therapeutics Inc - GuruFocus

Apr 30, 2025
pulisher
Apr 29, 2025

Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? - Nasdaq

Apr 29, 2025
pulisher
Apr 28, 2025

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL - Business Wire

Apr 28, 2025
pulisher
Apr 28, 2025

3 Healthcare Stocks That Concern Us - Yahoo Finance

Apr 28, 2025
pulisher
Apr 25, 2025

Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today - Benzinga

Apr 25, 2025
pulisher
Apr 25, 2025

March sees multiple phase III successes, boosting Corcept and Mineralys - BioWorld MedTech

Apr 25, 2025
pulisher
Apr 23, 2025

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - MSN

Apr 23, 2025
pulisher
Apr 23, 2025

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSEL - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 | CORT Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire

Apr 23, 2025
pulisher
Apr 22, 2025

Corcept: Maintaining Strong Buy Even After Q4 Revenue And Earnings Miss - Seeking Alpha

Apr 22, 2025
pulisher
Apr 21, 2025

Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes | CORT Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Diabetes Care Publishes Results From Prevalence Phase Of Corcept'S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - Yahoo Finance

Apr 21, 2025
pulisher
Apr 16, 2025

SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know - Barchart.com

Apr 16, 2025
pulisher
Apr 16, 2025

$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today - Benzinga

Apr 16, 2025
pulisher
Apr 15, 2025

It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha

Apr 15, 2025
pulisher
Apr 14, 2025

Corcept therapeutics director Daniel Swisher sells stock for $154,484 By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Corcept therapeutics director Daniel Swisher sells stock for $154,484 - Investing.com

Apr 14, 2025
pulisher
Apr 10, 2025

3 Biopharmaceutical Stocks Bucking the Sell-Off - MarketBeat

Apr 10, 2025
pulisher
Apr 09, 2025

Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter - Yahoo

Apr 09, 2025
pulisher
Apr 07, 2025

Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire

Apr 07, 2025
pulisher
Apr 07, 2025

Corcept begins trial for ovarian cancer treatment By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 06, 2025

How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4) - Benzinga

Apr 06, 2025
pulisher
Apr 05, 2025

Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Corcept Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CORT - Benzinga

Apr 04, 2025
pulisher
Apr 04, 2025

Commonwealth Equity Services LLC Has $700,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Corcept therapeutics officer sells $20.2 million in stock By Investing.com - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Piper Sandler lifts Corcept stock target to $131 post-study By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 03, 2025

Corcept Therapeutics’ chief development officer sells $77,639 in stock By Investing.com - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 02, 2025

Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares - Investing.com Australia

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept therapeutics president sells shares worth $10.1 million By Investing.com - Investing.com Canada

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept Therapeutics’ chief development officer sells $77,639 in stock - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept therapeutics president sells shares worth $10.1 million - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept therapeutics officer sells $20.2 million in stock - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success - markets.businessinsider.com

Apr 02, 2025
pulisher
Apr 02, 2025

Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Corient Private Wealth LLC Purchases New Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept Therapeutics (NASDAQ:CORT) Given New $142.00 Price Target at Canaccord Genuity Group - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - MSN

Apr 02, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics stock target raised to $150 by H.C. Wainwright - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics (CORT) Stock Surges Following Positive Tria - GuruFocus

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics (CORT) Surges 109% Following Positive Trial Results - GuruFocus

Apr 01, 2025
pulisher
Apr 01, 2025

U.S. Markets Ended Tuesday Mixed As monday.com Led, Corcept Therapeutics Lagged - Barron's

Apr 01, 2025
pulisher
Apr 01, 2025

Yum Brands (YUM) Seeks New CEO as Corcept (CORT) and Hut 8 (HUT) Shares Climb - GuruFocus

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics Unusual Options Activity For April 01 - Benzinga

Apr 01, 2025

Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Kapitalisierung:     |  Volumen (24h):